Evidence map›Paper›PMID 37546732›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Association study of human leukocyte antigen (HLA) variants and idiopathic pulmonary fibrosis.

Beatriz Guillen-Guio, Megan L Paynton, Richard J Allen, Daniel P W Chin, Lauren J Donoghue, Amy Stockwell, Olivia C Leavy, Tamara Hernandez-Beeftink, Carl Reynolds, Paul Cullinan and 37 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

47 authors at 20 institutions in 5 countries.

Beatriz Guillen-GuioDepartment of Population Health Sciences, University of Leicester, UK.
Megan L PayntonDepartment of Population Health Sciences, University of Leicester, UK.
Richard J AllenDepartment of Population Health Sciences, University of Leicester, UK.
Daniel P W ChinDepartment of Population Health Sciences, University of Leicester, UK.
Lauren J DonoghueGenentech, California, USA.
Amy StockwellGenentech, California, USA.
Olivia C LeavyDepartment of Population Health Sciences, University of Leicester, UK.
Tamara Hernandez-BeeftinkDepartment of Population Health Sciences, University of Leicester, UK.
Carl ReynoldsImperial College London, London, UK.
Paul CullinanImperial College London, London, UK.
Fernando MartinezWeill Cornell Medicine, New York, USA.
CleanUP-IPF Investigators of the Pulmonary Trials Cooperative
Helen L BoothUniversity College London Hospitals, London, UK.
William A FahyGlaxoSmithKline, London, UK.
Ian P HallUniversity of Nottingham, Nottingham, UK.
Simon P HartUniversity of Hull, Hull, UK.
Mike R HillUniversity of Oxford, Oxford, UK.
Nik HiraniUniversity of Edinburgh, Edinburgh, UK.
Richard B HubbardUniversity of Nottingham, Nottingham, UK.
Robin J McAnultyUniversity College London, London, UK.
Ann B MillarUniversity of Bristol, Bristol, UK.
Vidya NavaratnamDivision of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.
Eunice OballaGlaxoSmithKline, London, UK.
Helen ParfreyRoyal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
Gauri SainiUniversity of Nottingham, Nottingham, UK.
Ian SayersCentre for Respiratory Research, NIHR Nottingham Biomedical Research Centre, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Martin D TobinDepartment of Population Health Sciences, University of Leicester, UK.
Moira K B WhyteUniversity of Edinburgh, Edinburgh, UK.
Ayodeji AdegunsoyeUniversity of Chicago, Chicago, USA.
Naftali KaminskiYale School of Medicine, Connecticut, USA.
Ma Shwu-FanUniversity of Virginia, Virginia, USA.
Mary E StrekUniversity of Chicago, Chicago, USA.
Yingze ZhangUniversity of Pittsburgh, Pittsburgh, USA.
Tasha E FingerlinNational Jewish Health, Colorado, USA.
Maria Molina-MolinaServei de Pneumologia, Laboratori de Pneumologia Experimental, Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Barcelona, Spain.
Margaret NeighborsGenentech, California, USA.
X Rebecca ShengGenentech, California, USA.
Justin M OldhamUniversity of Michigan, Michigan, USA.
Toby M MaherNational Heart and Lung Institute, Imperial College London, London, UK.
Philip L MolyneauxNational Heart and Lung Institute, Imperial College London, London, UK.
Carlos FloresCentro de Investigacion Biomedica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.
Imre NothUniversity of Virginia, Virginia, USA.
David A SchwartzUniversity of Colorado Medicine, Colorado, USA.
Brian L YaspanGenentech, California, USA.
R Gisli JenkinsNational Heart and Lung Institute, Imperial College London, London, UK.
Louise V WainDepartment of Population Health Sciences, University of Leicester, UK.
Edward J HolloxDepartment of Genetics and Genome Biology, University of Leicester, UK.
University of Leicester · GBUniversity of Nottingham · GBInstituto de Salud Carlos III · ESImperial College London · GBNottingham University Hospitals NHS Trust · GBUniversity of Chicago · USUniversity of Pittsburgh · USUniversity of Southern California · USYale University · USCornell University · USGlaxoSmithKline (United Kingdom) · GBGuy's and St Thomas' NHS Foundation Trust · GBLung Institute · USRoyal London Hospital · GBUniversity College London · GBUniversity of Bristol · GBUniversity of Hull · GBUniversity of Michigan · USUniversity of Oxford · GBUniversity of Virginia · US

Funding

Elucidating the Genomic Determinants of Outcomes in Idiopathic Pulmonary FibrosisK23HL138190 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OLDHAM, JUSTIN M · 2017 to 2021
$914k
Improving Pulmonary Fibrosis Classification with Genomics Informed Phenotypic ClustersK23HL146942 · NHLBI · UNIVERSITY OF CHICAGO · PI ADEGUNSOYE, AYODEJI · 2020 to 2024
$810k
Derivation and validation of a clinical-molecular signature to predict fibrotic progression and treatment response in patients with autoimmune interstitial lung diseaseR56HL158935 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI OLDHAM, JUSTIN M · 2021 to 2021
$400k
Medical Research Council MC_PC_19004Medical Research Council MR/V00235X/1NHLBI NIH HHS K23 HL138190NHLBI NIH HHS K23 HL146942NHLBI NIH HHS R56 HL158935Wellcome Trust 201291/Z/16/Z
6 · The paper itself

Abstract

Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial pneumonia marked by progressive lung fibrosis and a poor prognosis. Recent studies have highlighted the potential role of infection in the pathogenesis of IPF and a prior association of the Methods: We performed a meta-analysis of associations of the HLA region with IPF risk in individuals of European ancestry from seven independent case-control studies of IPF (comprising a total of 5,159 cases and 27,459 controls, including the prior study of fibrotic interstitial pneumonia). Single nucleotide polymorphisms, classical HLA alleles and amino acids were analysed and signals meeting a region-wide association threshold Results: The meta-analysis of all seven studies identified four significant independent single nucleotide polymorphisms associated with IPF risk. However, none met the posterior probability for replication criterion. The Conclusion: Variation in the HLA region was not consistently associated with risk in studies of IPF. However, this does not preclude the possibility that other genomic regions linked to the immune response may be involved in the aetiology of IPF.

Identifiers

PMID37546732
PMCPMC10402235
OpenAlexW4385191907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.